Journals / Şişli Etfal Hastanesi Tıp Bülteni / 2004 / Cilt: 38 - Sayı: 3

The preliminary results of radio-chemotherapy in locally advanced gastric and pancreas cancer

Lokal-bölgesel ileri evre mide ve pankreas kanserli hastalarda radyokemoterapi önsonuçları

Pages
59–63
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

A multidisciplinary treatment approach for pancreas and stomach cancer, where modern radiotherapy techniques are used to minimize normal tissue complications was established in our institute, and the preliminary results were presented in this study.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Between February 2000 and November 2003 we treated 22 stomach and 10 pancreas cancer patients with definitive, adjuvant or palliative radiation and concurrent chemotherapy in the Department of Radiotherapy, Akdeniz University.
📊
Key Findings & Data:Median age of the gastric cancer patients was 53 (27-69); 15 were men and 7 were women.
💡
Conclusion & Impact:A multidisciplinary treatment approach for pancreas and stomach cancer, where modern radiotherapy techniques are used to minimize normal tissue complications was established in our institute, and the preliminary results were presented in this study.
🔬Design:Research Article
📍Scope:2000 Verileri
⚙️Variables:İlaç tedavisi · Mide neoplazmları · Pankreas neoplazmları

Abstract

Between February 2000 and November 2003 we treated 22 stomach and 10 pancreas cancer patients with definitive, adjuvant or palliative radiation and concurrent chemotherapy in the Department of Radiotherapy, Akdeniz University. Median age of the gastric cancer patients was 53 (27-69); 15 were men and 7 were women. Median age of the patients with pancreas cancer was 60 (48-78); 6 were men and 4 were women. The gastric and pancreas cancer patients received external beam radiation with linear accelerator to a median total dose of 4729 (4140-5400) cGy and 4896 (4140-5400) cGy, respectively. The gastric and pancreas cancer patients received 5FU+leucovarin and 5FU, respectively. Median follow-up of the gastric cancer patients was 20,6 months (5-46). Of the 22 patients with gastric cancer, fourteen patients (64%) died due to local-regional recurrence + metastasis, 4 patients (18%) were alive with local-regional recurrence, and the other 4 (18%) were alive free of disease. Median follow-up of the patients with pancreas cancer was 14,1 months (6-22). Of the 10 patients with pancreas cancer, 8 (80%) died due to local-regional recurrence, and 2 (20%) died due to local-regional recurrence + metastasis. A multidisciplinary treatment approach for pancreas and stomach cancer, where modern radiotherapy techniques are used to minimize normal tissue complications was established in our institute, and the preliminary results were presented in this study.

Özet

Şubat 2000 ile Kasım 2003 tarihleri arasında, Akdeniz Üniversitesi Tıp Fakültesi Radyasyon Onkolojisi Kliniği'nde 22 mide ve 10 pankreas kanserli hastaya definitif, post-operatif adjuvan veya palyatif radyoterapi (RT) ve es zamanlı kemote-rapi (KT) uygulandı. Mide kanserli hastaların 15'i erkek, T si kadındı ve ortalama yaşları 53 (27-69)'tü. Pankreas kanserli hastaların ise; 4'ü kadın ve 6'sı erkekti. Hastaların ortalama yası 60 (46-78) idi. Mide kanserli hastalara İSO cGyl gürü fraksiyon dozu ile tümör ve tümör yatağına ortanca total 4729 (4500-5580) cGy, pankreas kanserli hastalara ise 4896 (4140-5400) cGy eksternal RT lineer hızlandırıcı cihazı kullanılarak uygulandı. Mide kanserli hastalara eş zamanlı 5-FU ve 5-FU+LV ve pankreas kanserli hastalara da 5-FU ke-moterapisi uygulandı. Mide kanserli 22 hastanın ortalama iz-lem süresi 20.6 ay (5-46 ay) dir. Mide kanserli hastaların takibinde 22 hastadan 14'ü (%64) hastalığa (lokal bölgesel nüks ± uzak metastaz) bağlı kaybedildi, 4 hasta (%18) hastalıklı (lokal bölgesel nüks ± uzak metastaz) ile hayatta ve 4'ü (%18) de hastalıksız olarak hayattadır. Pankreas kanserli 10 hastanın ise ortalama izlem süreleri 14.1 ay (6-22 ay) olup takiplerinde hastalardan 8'i (%80) hastalığa (lokal bölgesel hastalık ± uzak metastaz) bağlı kaybedilirken, 2'si (%20) de lokal nüks ve metastatik hastalıkla yaşamını sürdürmektedir. Kurumumuzda pankreas ve mide kanserli hastalar için normal doku yan etkilerini en aza indiren modern radyoterapi tekniklerinin kullanıldığı multidisipliner tedavi yaklaşımı yerleşmiştir ve ön sonuçlar bu çalışmada verilmiştir.

🔖

Cite This Article

ATAMAN, F., ŞİMŞİR, V., ŞEN, C. A., BOZCUK, H., ÖĞÜŞ, M., ERDOĞAN, O., SAVAŞ, B. (2004). The preliminary results of radio-chemotherapy in locally advanced gastric and pancreas cancer. Şişli Etfal Hastanesi Tıp Bülteni, Cilt: 38 - Sayı: 3, 59–63. https://ajindex.com/articles/363579

References (14)

  1. Moosu AR.: Surgical treatment ni* pancreatic cancer. Am S Surg. 152: 163, 1986
  2. S pert, i C, Pasquali C. Chicriclietli F.: Value of IN-fluoro- deoxygluco.se positron emission tomography in manage¬ment of patients with cystic tumors of the pancreas. Ann Surg. 234: 675-680, 2001
  3. Evans DB. Pistéis 1'WT, Lee.IE: Master of Surgery: Pancieatieoduodeneclomy (Whipple operation) and total pancreatectomy for cancer. 1st ed. New York NY, Lippin- cott, Williams and Wilkins, 200!, pp: 1299-1318
  4. Allema RH, Reinders ME, van Gulik TM.: Prognostic factors lor survival after pancreaticoduodenectomy for patients with 5. Willet CG, Lewandrowski K, Warshaw AL.: Resection margins in carcinoma of the head of the pancreas. Impli¬cations for radiation therapy. Ann Surg 217: 144-148, 1993
  5. Michael C. Perry: Pancreatic Cancer. ASCO Educational Book Thirty-Ninth Annual Meeting Chicago, IL, 2003, pp: 404-411 7. Gastrointestinal Tumor Study Group: Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gast¬rointestinal Tumor Study Group. Cancer 59: 2006-2010, 1987
  6. Gunderson LL, Sosin H.: Adenocarcinoma of the stomach: Areas of failure in a reoperation series (second or symtomatic looks) Ciinicopathologic correlation and implications for adjuvant therapy. !nl J Radiat Oncol Biol Rhys. 1-9, 1982
  7. Hartley LC, Evans E, Windsor CJ.: Factors influencing prognosis in gastric cancer. Aust NZ J Surg. 57: 5-12, 1987
  8. Dockerty MB.: Pathologic aspects of primary malignant neoplasm of he stomach. In: Remine WH, Priestly JT, Berkson J, eds. Cancer of the stomach. Philadelphia: WB Saunders, 173, 1964
  9. Kennedy BJ.: TNM classification for.stomach cancer. Cancer 26: 971. 1970
  10. Nagatomo T, Amee 1, LuITu S.; Histologic criteria of serosal rupture and prognosis in gastric carcinoma. Can¬cer 29: 180, 1969
  11. Ajani J A, Radiation Therapy Oncology Group: Plase II Study of Preoperative Chemotherapy and Chemoradiot- berapy in Patients with Potentially Resectable Adenocar¬cinoma of the Stomach, RTOG 9904
  12. Hermans J, Bonenkamp JJ., Boon M.: Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncoi. 11: 1441-1447, 1993
  13. Perez CA, Brady LW, Halperin EC, Schimidt-Ullrich RK: Stomach: Principles and Practice of Radiation Oncology, 4th eel. Philadelphia, Lippincott Williams and Wiîkins, 2004, pp: 1574-1589
  14. Mac Donald JS, Smalley SR, Benedefti J